Lymphoma Research Foundation Gala Raises $1 million for Research

The Lymphoma Research Foundation, the nation’s largest non-profit organization devoted exclusively to funding innovative research and serving the lymphoma community, held its annual gala on Oct. 8, 2013 at New York City’s Chelsea Piers.

More than 300 guests celebrated the contributions of the evening’s honorees in advancing the Foundation’s mission of eradicating lymphoma and serving people affected by the disease.

Fundraising for lymphoma research

The Foundation's signature "Raise it for Research" auction was conducted by Sotheby’s auctioneer C. Hugh Hildesley. In this auction, attendees pledge funds for lymphoma research ranging from $500 to $100,000. It took a matter of minutes to raise more than $335,000 for lymphoma-specific research.

"Investing in lymphoma research is critical to discovering improved therapies and ultimately a cure,” said Steven J. Prince, LRF Chairman of the Board. “The outpouring of support during Raise it for Research highlighted our shared commitment to eradicate lymphoma and underscored the important role the Foundation plays in funding the promising research that our Scientific Advisory Board recommends."

Among the evening's many honorees were Dr. Bruce Cheson, former Chair of the Lymphoma Research Foundation’s Scientific Advisory Board and Deputy Chief, Division of Hematology-Oncology and Head of Hematology at the Lombardi Comprehensive Care Center at Georgetown University Hospital, and his wife Christine. The Chesons received the Distinguished Service Award in recognition for all that they have done to advance lymphoma research, most notably the founding of the Lymphoma Research Ride in Montgomery County, Md., which has raised more than $3 million for lymphoma research over the past seven years.

Ultimately the gala raised nearly $1 million for lymphoma research.

Photo Credit: Dan D'Errico Photography

Source: PR Web

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap